CG Oncology is thrilled to welcome some key leaders to our organization. These new hires will be critical in our mission of Attacking Bladder Cancer for a Better Tomorrow™!
Welcome to CG Oncology:
Josh Patterson - General Counsel & Chief Compliance Officer
Bob Lapetina - VP, Financial Planning and Analysis
Sarah Connors - Vice President, Communications and Patient Advocacy
Serial Biotech Executive/Entrepreneur/Investor. President-TiE Boston, Chairman, Stalicla, SA, Consulting CEO GelMEDIX. Ex President &CEO and Board member of Immunome (NASDAQ:IMNM) and TARIS Biomedical
It's not to late to join the conversation! Register now for this week's webinar to hear from oncology clinical trial patient Mike Herman, patient advocate and founder of Speaking On Cancer Patient Advocacy. You’ll also here more on:
🔍The Site's Lens: Amy Avergas MSIT, MBA, Manager of Oncology Research at Medstar Health Research Institute, will share her insights into how Greenphire's participant payment solution, ClinCard, is changing the game for patients and research sites alike.
💡 Technology Enablement: Meet Greenphire's very own PhDs on staff, Michael Rogan, PhD, LCSW and Clay Williams, creators of GreenSpace. Discover how this patient-powered registry, utilized by organizations like MBCA, is shaping the future of oncology research.
It's no secret that there are significant gaps in the patient journey. That’s why we are on a mission to bridge them. Don't miss out - register today! https://lnkd.in/eVTDtyCc
We all agree, that patients have to be first before clinical trials are being planned, when doctors discuss therapy options, when monitoring patients through difficult side effect management, supporting them in molecular diagnostic and early palliative care. Patient community collaboration with industry has come a long way and is working well, patient centricity has become a strong topic. Cancer patients need guidance and good communication in dealing with side effects, specially those with advanced and metastatic disease. We all agree, I thought…until I visited a Symposium for treatment options in metastatic breast cancer, where oncologists were being asked what in their opinion the biggest outstanding question related to a new drug for metastatic breast would be? How disappointing to see the voting: Top two were „identification of biomarkers and sequencing different agents“ and with only 1% at the end of the voting list was „AE management“ Today we have great treatment options with longer survival. But this comes with a price, adverse events and sometimes serious adverse events. Health Care Professionals have to be aware of how much patients depend on their guidance and support. This is an important message WE STILL HAVE TO DO MORE FOR PATIENTS!
Head Oncology Europe and Canada at Daiichi Sankyo Europe GmbH
What does patient centricity mean to you?
Let me share what being truly patient centric means to me and why it matters to us at Daiichi Sankyo.
Patients' experiences, preferences and needs are diverse and individual. To understand them, it is important to create platforms where all relevant stakeholders can come together to enter into an exchange.
Such a platform at Daiichi Sankyo Europe GmbH is the European Oncology Patient Advocacy Forum, which took place last week. Over two days, patient advocates and Daiichi Sankyo colleagues met to discuss changes that matter to cancer patients and their caregivers and to capture the results in a roadmap.
As a learning organization, it is crucial for us to systematically seek dialogue and translate our insights into meaningful actions. After all, these findings help us to work with our partners to improve the lives of patients and their caregivers.
What does patient centricity mean to you? I’m looking forward to hear your perspective!
#PatientCentricity#Oncology#Collaboration#ChangesThatMatter
What does patient centricity mean to you?
Let me share what being truly patient centric means to me and why it matters to us at Daiichi Sankyo.
Patients' experiences, preferences and needs are diverse and individual. To understand them, it is important to create platforms where all relevant stakeholders can come together to enter into an exchange.
Such a platform at Daiichi Sankyo Europe GmbH is the European Oncology Patient Advocacy Forum, which took place last week. Over two days, patient advocates and Daiichi Sankyo colleagues met to discuss changes that matter to cancer patients and their caregivers and to capture the results in a roadmap.
As a learning organization, it is crucial for us to systematically seek dialogue and translate our insights into meaningful actions. After all, these findings help us to work with our partners to improve the lives of patients and their caregivers.
What does patient centricity mean to you? I’m looking forward to hear your perspective!
#PatientCentricity#Oncology#Collaboration#ChangesThatMatter
Whether you're getting started in lung cancer patient advocacy or already a seasoned pro, you'll want to watch this video with Jill Feldman and Dusty Donaldson. Called, "Learning from the legends of lung cancer advocacy," this discussion covers everything from top tips, working with others, resources & more.
This video is part 2 of a 3-part series from our Co-founder and Chair, Yvonne Diaz, following the award of an IASLC Patient Educational Award.
Don't miss this: 📺 https://lnkd.in/ex5UmW2C#PatientAdvocacy#lungcancer#hope#PatientVoice#StrongerTogether
Are you a leader at a patient organization? If so, you won’t want to miss the third installment of our five-part Patient Organization Webinar Series. Join fellow leaders for Changing Oncology Landscape: Considerations for Oncology Organizations and Registries.
📅 Wednesday, June 26, 2024, 11:00 AM EDT
📌 Webinar
🎙️ Audra Moran, Kapila Viges, Jeff Hodge, Murray Aitken
🔗 Register here: https://lnkd.in/ehRnEdkj#PatientAdvocacy#PatientOutcomes
Explore the 2023 ACCC Impact Report to discover valuable insights on our mission, innovations, comprehensive cancer care resources, advocacy efforts, and our focus for the future of cancer care. Read now: https://bit.ly/43mm1ON
Join me and my panel of experts next week at the #SCRS Diversity and Oncology Summits! Our topic will be: Best Practices For Streamlined Budget Negotiations & Approvals. See you there!
Patients, AI and RWE were all hot topics at this year’s ASCO meeting, alongside a number of other prominent themes.
We had over 20 colleagues at ASCO interacting with patient advocacy groups, meeting with academic, clinical and pharma leaders, and attending great sessions.
Contact us if you’d like a walkthrough of some of the noteworthy themes and key discussions from this year’s meeting.
https://buff.ly/446UD6m#asco2023#asco#oncologyresearch#oncology#patientfocus#realworldevidence#ascoreport
Academic | Entrepreneur | Educator
1moSo exciting. It will be great to see how adenovirus vector engineering can expand their interventional possibilities.